HANXBIO-B

Hanx Biopharmaceuticals experienced a spike-and-drop session in the morning: opened at HKD 29.50, the day's high, then slid to close the morning at HKD 27.62, down 0.22%, with an intraday low of HKD 26.08 representing an 11.5% drop from the open. The decline came despite the company's recent share repurchases, with multiple buybacks disclosed at average prices between HKD 28.91 and HKD 28.63, indicating the current price has fallen below repurchase costs. Listed less than eight months, the stock still boasts a 61.9% YTD gain, but is now 16.15% below its 52-week high of HKD 32.94 and has breached both the 20-day MA (HKD 27.932) and 60-day MA (HKD 28.145), signaling technical weakness. On the news front, the company recently announced an AI-driven drug discovery collaboration with TwinEdge Bioscience for HX009 and was added to the FTSE Global Micro Cap Index, yet these catalysts failed to lift the stock. Financially, Hanx remains loss-making with a PE of -25.55x and a PB of 4.8x, and a total market cap of approximately HKD 3.7 billion. While the core pipeline candidate HX009, a PD-1/SIRPα bifunctional fusion protein, and the AI collaboration represent potential long-term value drivers, near-term sentiment remains subdued.

Hanx Biopharmaceuticals (3378.HK) opened lower in the morning session on the Hong Kong stock exchange, trading at HKD 27.98, up 7.2% from the prior close of HKD 26.10. However, the stock has retreated 15.06% from its 52-week high of HKD 32.94 and is trading below its 20-day moving average of HKD 28.252, indicating overhead resistance. The company has been actively repurchasing shares, with at least six buyback disclosures in the past month at average prices between HKD 27.96 and HKD 28.96, and has announced an AI-driven collaboration with TwinEdge Bioscience for its core product HX009, while also being added to the FTSE Global Micro Cap Index. Despite these positive catalysts, the stock remains below key moving averages. With a market cap of approximately HKD 3.75 billion, negative P/E of -25.86x, and P/B of 4.86x, the stock has gained 64.01% year-to-date, though trading volume was extremely thin at just 300 shares and HKD 8,440 turnover in the morning session.

翰思艾泰今日下午盘急速拉升，最终收报 28.70 港元，较前收 26.90 上涨 6.69%，上午盘曾探低至 26.020，形成深 V 反转。驱动主因是公司宣布与 TwinEdge Bioscience 就核心产品 HX009 开展 AI 驱动药物开发合作，叠加近期连续多笔股份回购（均价 28.63-28.96 港元）及被纳入 FTSE 全球微型股指数提升关注度，下午盘成交放量至 6200 股，占全日总量 72%。当前股价 28.70 逼近 20 日均线 28.378 和 60 日均线 28.468，距 52 周高 32.94 仅低 12.87%，YTD 涨幅达 68.23%，但 PB 达 4.98 倍且 PE 为负，估值压力仍存。

HANX Biopharma opened lower and extended losses into the afternoon session, closing at HK$26.18, down 5.01% from the prior close of HK$27.56. The decline occurred despite a series of recent share buybacks, as the market digested news including the company's inclusion in the FTSE Global Micro Cap Index and a collaboration with TwinEdge Bioscience on AI-driven HX009 development, triggering profit-taking. The stock hit an intraday low of HK$26.18, a post-listing trough, after briefly touching the prior close of HK$27.56 at the morning open before sliding steadily. The current price of HK$25.68 sits 22.04% below the 52-week high of HK$32.94 and below both the 20-day MA of HK$28.24 and 60-day MA of HK$28.53, though it remains up 50.53% year-to-date, suggesting underlying long-term support. The company has a total market cap of approximately HK$3.45 billion, a P/B of 4.46x, and a negative P/E of -23.77x, as profitability remains elusive.

翰思艾泰（3378.HK）今日高开低走，盘中震荡下行，主要受港股整体疲软拖累，早盘从 28.240 港元高点快速回落，午后最低触及 26.380 港元，最终收报 26.420 港元，较前收 28.260 港元下跌 6.5%。公司近期频繁进行股份回购，近一个月内已发布多项翌日披露报表，回购均价在 28.63 至 28.96 港元区间，显示管理层对股价的支撑意愿。同时，公司宣布与 TwinEdge Bioscience 合作利用 AI 技术推进核心产品 HX009 的研发，并获纳入 FTSE 全球微型股指数，提升国际关注度。不过，当前股价已跌破所有回购均价，并低于 52 周最高点 27.020 港元，市盈率-24.4 倍，市净率 4.58 倍，换手率仅 0.03%，市场交投清淡，短期反弹动能不足。